IDH2 and glioblastoma: IDH-wildtype, and one of: TERT promoter mutation; chromosome 7+/10-; or EGFR amplification, defines molecular GBM irrespective of histologic gradeMGMT promoter methylation is aprognostic biomarker independent of treatment with alkylating chemotherapy and a predictive biomarker of benefit from alkylating chemotherapy in patients with IDH-wildtype glioblastoma